Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma Eisai Feb 25, 2022 16:26 HKT/SGT Read More
Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi's First Dedicated Compact Proton Therapy System Hitachi, Ltd. Feb 02, 2022 08:03 HKT/SGT Read More
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021 Eisai Feb 01, 2022 16:43 HKT/SGT Read More
エーザイ、｢レンビマ(R)｣｢キイトルーダ(R)｣との併用療法について、進行性腎細胞がん一次療法として台湾において承認を取得 Eisai Jan 31, 2022 10:00 JST Read More
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma Eisai Jan 31, 2022 08:47 HKT/SGT Read More
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases Eisai Jan 28, 2022 11:43 HKT/SGT Read More
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM Eisai Jan 28, 2022 08:40 HKT/SGT Read More
エーザイ、｢レンビマ(R)｣と｢キイトルーダ(R)｣の併用療法について進行性子宮内膜がんを対象とした臨床第III相309試験/KEYNOTE-775試験の結果がthe New England Journal of Medicineに掲載 Eisai Jan 20, 2022 09:00 JST Read More
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Eisai Jan 20, 2022 08:56 HKT/SGT Read More
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time Eisai Jan 19, 2022 16:36 HKT/SGT Read More
エーザイ、DIAN-TUが実施する優性遺伝アルツハイマー病に対する抗MTBRタウ抗体E2814の臨床第II/III相試験に最初の被験者が登録 Eisai Jan 19, 2022 10:00 JST Read More
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study Eisai Jan 19, 2022 09:06 HKT/SGT Read More
